Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.3K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.3K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.6K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.6K
Drug Therapy01:28

Drug Therapy

331
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
331

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Role of Perfusion Parameters on Outcomes and Safety of Endovascular Therapy in Posterior Cerebral Artery Stroke.

Stroke·2026
Same author

Early multimodal predictors of good neurological outcome in comatose patients after cardiac arrest: a prospective single-center cohort study.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Positron emission tomography for diagnosing cerebrovascular disorders: a scoping review.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Italian Olfactory Identification Test in Systemic Lupus Erythematosus: Association of Olfactory Impairment With Chronic Damage and Anti-β<sub>2</sub>-Glycoprotein I Antibodies.

ACR open rheumatology·2026
Same author

Idebenone in Rapid Eye Movement Sleep Behavioral Disorder for Parkinson's Disease Prevention.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Interaction of Intraprocedural Antiplatelets and Intravenous Thrombolysis in Acute Intracranial Stenting: RESISTANT Registry Subanalysis.

Annals of clinical and translational neurology·2026

Related Experiment Video

Updated: Mar 2, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K

Levodopa in Parkinson's Disease: Current Status and Future Developments.

Nicola Tambasco1, Michele Romoli1, Paolo Calabresi1,2

  • 1Clinica Neurologica, Azienda Ospedaliera-Universita di Perugia, Perugia, Italy.

Current Neuropharmacology
|May 13, 2017
PubMed
Summary
This summary is machine-generated.

Levodopa (LD) is the standard Parkinson's treatment, but motor fluctuations occur. New formulations and delivery methods aim for continuous dopaminergic stimulation and rapid symptom relief.

Keywords:
DM-1992IPX066LCIGODM-101Parkinson`s diseaseXP21279levodopapharmacology.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.5K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.6K

Related Experiment Videos

Last Updated: Mar 2, 2026

Ole Isacson: Development of New Therapies for Parkinson's Disease
23:53

Ole Isacson: Development of New Therapies for Parkinson's Disease

Published on: April 29, 2007

8.5K
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
05:51

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

4.5K
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
06:45

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

3.6K

Area of Science:

  • Neurology
  • Pharmacology
  • Drug Development

Background:

  • Levodopa (LD) remains the gold standard for Parkinson's Disease (PD) treatment since the 1960s.
  • Long-term LD use often leads to motor fluctuations, significantly impacting patient quality of life.
  • These fluctuations are linked to LD's pharmacokinetic properties, including short half-life and narrow therapeutic window.

Purpose of the Study:

  • To review advancements in LD treatment strategies aimed at overcoming long-term complications.
  • To summarize progressive improvements in LD pharmacokinetics and delivery since the 1960s.

Main Methods:

  • Systematic review of research and clinical trials focused on improving LD pharmacokinetics.
  • Analysis of historical and recent therapeutic approaches to enhance LD efficacy and patient outcomes.

Main Results:

  • Introduction of peripheral amino acid decarboxylase (AADC) inhibitors to optimize central LD concentration and reduce side effects.
  • Catechol-O-methyltransferase (COMT) inhibitors have been developed to extend LD half-life and improve bioavailability.
  • Ongoing research explores continuous dopaminergic stimulation via combined oral therapies, intra-duodenal gels, and novel administration routes (nasal, intrapulmonary, subcutaneous) and extended-release (ER) formulations.

Conclusions:

  • Recent advancements focus on new oral and non-oral LD formulations and delivery systems.
  • Key objectives include achieving continuous dopaminergic stimulation and enabling rapid LD delivery for immediate symptom control.